Jump to content

Recommended Posts

Posted

It is in the process. WHO requires more data from Bharath Biotech to put Covaxin in the Emergency usage list. May take 6 or more months.

Posted
1 minute ago, BalayyaTarak said:

antey they are doing mass testing on public tilll now ?

Basically all COVID vaccines produced in the world are only for emergency use. None is approved. 
 

Covaxin just needs more people to be inoculated, so WHO can put it in Emergency list. 

Posted

I am surprised to see that Bharat Biotech had taken that initiative so late. I think the Chinese vaccine also only got recently approved. WHO queries could be related to anything including clinical study designs etc. 

Posted

June lo Covaxin said it will release 3rd phase trail data and submit it for Peer Review. Not sure why they took this long when they are already publishing 78% efficacy from their Trails in their website and official statements. But they are little late on publishing these data to Public. Hopefully by end of June it should be done. 

Posted
9 minutes ago, bob9 said:

June lo Covaxin said it will release 3rd phase trail data and submit it for Peer Review. Not sure why they took this long when they are already publishing 78% efficacy from their Trails in their website and official statements. But they are little late on publishing these data to Public. Hopefully by end of June it should be done. 

Under 18 years vaccine trails avi.. 

Posted
20 hours ago, bob9 said:

June lo Covaxin said it will release 3rd phase trail data and submit it for Peer Review. Not sure why they took this long when they are already publishing 78% efficacy from their Trails in their website and official statements. But they are little late on publishing these data to Public. Hopefully by end of June it should be done. 

The key issue here is with the study design and nature of population involved in these studies. You need to align on these designs with various authorities. India wants separate studies done in our country because of which they might have ended up doing Indian studies first. Instead, they could have gone with mulitcountry study aligned on design with various authorities simultaneously which is easy to say but difficult to come up with. Because of CDSCO stand, it is getting difficult for the approval of vaccine manufacturers like Pfizer and Moderna as they seem to not have studies with Indian population.

Archived

This topic is now archived and is closed to further replies.

  • Recently Browsing   0 members

    • No registered users viewing this page.
×
×
  • Create New...